# Can You Take a GLP-1 With Polycystic Kidney Disease? Not as a Treatment Can you take a GLP-1 with polycystic kidney disease? One 320-pair cohort found no rise in kidney injury | reviews say it is not a treatment for ADPKD. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/can-you-take-a-glp1-with-polycystic-kidney-disease Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Can You Take a GLP-1 With Polycystic Kidney Disease? Not as a Treatment One matched study of 320 pairs found a higher eGFR on semaglutide and no rise in kidney injury. The eGFR is calculated from creatinine, which falls when muscle does, and reviews say it is not a treatment. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Outcomes built on creatinine, and outcomes that are not · eGFR at follow-up · 57.52 vs 50.93, p = 0.013 · progression to stage 5 · HR 0.447 (0.230-0.872) · end-stage kidney disease · no significant difference · acute kidney injury · no significant difference · 320 matched pairs. Creatinine comes from muscle. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - No trial has yet published GLP-1 results in polycystic kidney disease; the human outcome evidence is one matched cohort of 320 pairs. - Semaglutide users had a higher follow-up eGFR, 57.52 against 50.93 mL/min/1.73 m2, and less progression to stage 5 disease, hazard ratio 0.447. - End-stage kidney disease, acute kidney injury and urinary tract infection showed no significant difference. - Both favorable outcomes are calculated from creatinine, which falls when muscle is lost, and the authors call the results hypothesis-generating. - A 2026 review says GLP-1 therapy should not currently be regarded as a treatment for the disease. People with polycystic kidney disease do take GLP-1 drugs, for weight or for diabetes, and the one matched study of them found no signal of kidney harm across 320 pairs [\[1\]](https://thisglp.com/research/can-you-take-a-glp1-with-polycystic-kidney-disease#ref-1). Acute kidney injury was no more common on semaglutide, and follow-up eGFR was higher, 57.52 against 50.93 mL/min/1.73 m2. What that study cannot show is that the drug protects the kidneys, and the reviews on the question are clear that a GLP-1 is not a treatment for the disease itself. The decision about taking one sits with a nephrologist, for the same reasons it does in [later-stage kidney disease on dialysis](https://thisglp.com/research/can-you-take-a-glp1-on-dialysis). ## The study, and who was in it Autosomal dominant polycystic kidney disease is inherited, progressive, and short on treatment options, and semaglutide has shown kidney benefits in other populations, which is what prompted researchers to look [\[1\]](https://thisglp.com/research/can-you-take-a-glp1-with-polycystic-kidney-disease#ref-1). They searched a large research network for adults with the disease between 2000 and 2024 and excluded anyone on an SGLT2 inhibitor, tolvaptan or another GLP-1. Among 45,613 patients, 323 eligible semaglutide users remained, and 320 of them were matched one to one against non-users. Excluding tolvaptan matters, because tolvaptan is the drug that treatment of this disease is built around. The study compares semaglutide against no particular treatment rather than against the standard of care, and it says nothing at all about taking the two together. ## What moved, and what did not Follow-up eGFR came out higher on semaglutide, and progression to stage 5 chronic kidney disease was lower, with a hazard ratio of 0.447 and a confidence interval from 0.230 to 0.872. Volume depletion and death from any cause were also less common among the users. End-stage kidney disease, acute kidney injury and urinary tract infection showed no significant difference either way. Two readings of the same pattern The eGFR in this study is calculated from creatinine, a waste product of muscle, and semaglutide weight loss takes muscle off along with fat, so the number can rise with the kidney filtering exactly as before. The outcomes that moved are the ones built on creatinine, and end-stage disease, which is not, did not move. That fits a measurement artifact, and it also fits a hard endpoint too rare to show up in 320 pairs, and the authors themselves call their results hypothesis-generating. The same creatinine problem runs through other kidney results on this site, including [the contrast kidney injury cohort](https://thisglp.com/research/do-glp1-drugs-prevent-contrast-kidney-injury), and the muscle side of it is covered in [the muscle loss guide](https://thisglp.com/research/do-you-lose-muscle-on-a-glp1). A filtration marker that does not come from muscle, such as cystatin C, is the usual way to separate the two readings, and it is not among the outcomes the study reports. ## What the reviews say Two reviews have looked at whether these drugs could slow the disease. The first points to animal findings and to the metabolic changes the drugs produce, in weight, blood pressure and inflammation, as reasons for interest. It concludes that further clinical studies are needed on both efficacy and safety before the drugs could be used for it [\[2\]](https://thisglp.com/research/can-you-take-a-glp1-with-polycystic-kidney-disease#ref-2). The second goes further into the biology, arguing that obesity and visceral fat may shape how fast cysts grow and kidney function falls, which would make GLP-1 drugs plausible candidates alongside tolvaptan rather than substitutes for it [\[3\]](https://thisglp.com/research/can-you-take-a-glp1-with-polycystic-kidney-disease#ref-3). It describes early-phase trials in progress, lists co-administration with tolvaptan among the open questions, and states plainly that GLP-1 therapy should not currently be regarded as a treatment for the disease. ## Where that leaves someone with the disease For a person with polycystic kidney disease who is being offered a GLP-1 for weight or diabetes, this cohort flagged no kidney harm and the reviews promise no kidney benefit. The heavier kidney claims for this drug come from [the FLOW trial in diabetic kidney disease](https://thisglp.com/research/semaglutide-and-kidney-disease), a different condition. The question still unanswered is whether the drug changes the course of the cysts themselves, and that is what the trials now under way were designed to find out. ## Frequently asked Can you take a GLP-1 with polycystic kidney disease? People with the disease do take them for weight or diabetes. The one matched study of 320 pairs found no rise in acute kidney injury, but no trial has reported results and the decision belongs with a nephrologist. Does semaglutide slow polycystic kidney disease? Not shown. Follow-up eGFR was higher and stage 5 progression lower on semaglutide, but both are calculated from creatinine, which falls when muscle is lost, and end-stage kidney disease did not differ. Is a GLP-1 a treatment for ADPKD? No. A 2026 review states that GLP-1 therapy should not currently be regarded as a treatment for the disease, and early-phase trials are still in progress. Can you take a GLP-1 with tolvaptan? That has not been answered. The cohort excluded tolvaptan users, and a 2026 review lists co-administration with tolvaptan among the open questions for trials. ## Sources 1. \[1\] Chen TP, Tsai SF (2026). Association of semaglutide use with kidney outcomes in adults with ADPKD: A propensity score-matched real-world study Science Progress. [PMID 42648283](https://pubmed.ncbi.nlm.nih.gov/42648283/) 2. \[2\] Ali H, Alahmad B, Al-Mulla F (2025). Can GLP-1 receptor agonists slow the progression of Autosomal Dominant Polycystic Kidney Disease? BMC Nephrology. [PMID 40468228](https://pubmed.ncbi.nlm.nih.gov/40468228/) 3. \[3\] Corrêa LMA, Brandão LKV, Delmiro Silva YR, Ferreira GD, Mazur GR, Arruda SLP, et al. (2026). GLP-1 receptor agonists in ADPKD: from metabolic rationale to phenotype-enriched translational testing Translational Research. [PMID 42398811](https://pubmed.ncbi.nlm.nih.gov/42398811/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)